Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

77.28USD
24 Feb 2017
Change (% chg)

$-0.17 (-0.22%)
Prev Close
$77.45
Open
$76.84
Day's High
$77.35
Day's Low
$76.82
Volume
2,748,937
Avg. Vol
3,435,906
52-wk High
$83.58
52-wk Low
$66.93

NVS

Chart for NVS

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $202,648.20
Shares Outstanding(Mil.): 2,627.11
Dividend: 2.75
Yield (%): 3.55

Financials

  NVS Industry Sector
P/E (TTM): 27.62 28.84 29.63
EPS (TTM): 2.80 -- --
ROI: 6.21 13.44 12.96
ROE: 8.84 14.34 14.11

Novartis wins CHMP nod for drug combo against some lung cancers

ZURICH Swiss drugmaker Novartis's drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lung cancer after a key committee on Friday published a recommendation to expand the combination's indications.

Feb 24 2017

Novartis wins CHMP nod for drug combo against some lung cancers

ZURICH, Feb 24 Swiss drugmaker Novartis's drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lung cancer after a key committee on Friday published a recommendation to expand the combination's indications.

Feb 24 2017

Novartis cancer drug Zykadia gets FDA priority review

ZURICH The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday.

Feb 23 2017

Novartis cancer drug Zykadia gets FDA priority review

ZURICH, Feb 23 The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday.

Feb 23 2017

BRIEF-Novartis says Zykadia drug gets FDA priority review

* Novartis drug zykadia receives fda priority review for first-line use in patients with alk+ metastatic nsclc

Feb 23 2017

Merck stopping late stage study as another Alzheimer's drug fails

Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

Feb 14 2017

UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails

Feb 14 Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

Feb 14 2017

Teva's new boss has bitter medicine to administer

LONDON (Reuters Breakingviews) - U.S. President Donald Trump has criticised drugmakers for getting away with murder. Israeli group Teva, which has lost its second chief executive in four years, looks guiltier of self-harm.

Feb 07 2017

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

LONDON Emma Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

Feb 06 2017

New GlaxoSmithKline CEO prepares for R&D choices, potential deals

LONDON, Feb 6 Emma Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.

Feb 06 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.73 +1.03
Pfizer Inc. (PFE.N) $34.26 +0.20
Merck & Co., Inc. (MRK.N) $66.16 +0.31
Roche Holding Ltd. (ROG.S) CHF245.20 +0.10
Roche Holding Ltd. (RO.S) CHF248.50 +0.30
Abbott Laboratories (ABT.N) $45.68 +0.28
Sanofi SA (SASY.PA) €80.58 +0.45
AstraZeneca plc (AZN.L) 4,609.00 +8.50
GlaxoSmithKline plc (GSK.L) 1,639.50 +7.00
Eli Lilly and Co (LLY.N) $82.87 +0.32

Earnings vs. Estimates